MeSH term
Frequency | Condition_Probility | Adult | 33 | 0.0 |
Humans | 350 | 0.0 |
Male | 78 | 0.0 |
Middle Aged | 28 | 0.0 |
Reference Values | 5 | 0.0 |
Risk Factors | 7 | 0.0 |
Smoking/adverse effects | 2 | 0.0 |
Amino Acid Substitution | 3 | 0.0 |
Animals | 211 | 0.0 |
DNA/chemistry/*metabolism | 2 | 3.0 |
Mice | 100 | 0.0 |
Protein Structure, Tertiary | 6 | 0.0 |
Research Support, Non-U.S. Gov't | 239 | 0.0 |
Aged | 16 | 0.0 |
Female | 88 | 0.0 |
Genotype | 15 | 0.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Receptors, Aryl Hydrocarbon/*genetics | 25 | 80.0 |
Survival Rate | 2 | 0.0 |
Adolescent | 8 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Comparative Study | 37 | 0.0 |
Data Interpretation, Statistical | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Software | 3 | 1.0 |
Time Factors | 16 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Gene Expression Regulation | 8 | 0.0 |
Ligands | 39 | 1.0 |
Rats | 59 | 0.0 |
Receptors, Cytoplasmic and Nuclear/genetics/*metabolism | 3 | 6.0 |
Amino Acid Sequence | 44 | 0.0 |
Base Sequence | 65 | 0.0 |
Biological Markers | 4 | 0.0 |
DNA, Complementary/chemistry | 3 | 1.0 |
Environmental Pollutants/*toxicity | 11 | 29.0 |
Mice, Inbred C57BL | 19 | 0.0 |
Molecular Sequence Data | 68 | 0.0 |
Molecular Weight | 6 | 0.0 |
Receptors, Aryl Hydrocarbon/chemistry/*genetics/metabolism | 2 | 66.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 33 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 173 | 0.0 |
Sequence Homology, Amino Acid | 20 | 0.0 |
Species Specificity | 18 | 0.0 |
Cells, Cultured | 20 | 0.0 |
Cytochrome P-450 CYP1A1/genetics | 19 | 19.0 |
DNA Primers/chemistry | 5 | 0.0 |
*DNA-Binding Proteins | 58 | 3.0 |
Gene Expression Regulation/*drug effects | 7 | 1.0 |
Hepatocytes/*drug effects/metabolism | 3 | 27.0 |
RNA, Messenger/metabolism | 31 | 0.0 |
Rats, Sprague-Dawley | 22 | 0.0 |
Receptors, Aryl Hydrocarbon/biosynthesis | 2 | 40.0 |
Reverse Transcriptase Polymerase Chain Reaction | 31 | 0.0 |
Transcription Factors/*genetics/metabolism | 4 | 1.0 |
Apoptosis/*drug effects | 6 | 0.0 |
Benzoflavones/pharmacology | 9 | 18.0 |
Dose-Response Relationship, Drug | 34 | 0.0 |
Mice, Inbred DBA | 3 | 0.0 |
Mice, Knockout | 6 | 0.0 |
Polychlorinated Biphenyls/*toxicity | 4 | 25.0 |
Receptors, Aryl Hydrocarbon/genetics/*metabolism | 24 | 92.0 |
Biological Assay/methods | 4 | 10.0 |
Cytochrome P-450 CYP1A1/biosynthesis | 10 | 33.0 |
Enzyme Induction | 31 | 5.0 |
*Gene Expression Regulation | 10 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Transfection | 45 | 0.0 |
Tumor Cells, Cultured | 94 | 0.0 |
Alleles | 8 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics | 5 | 1.0 |
DNA Primers | 18 | 0.0 |
Finland | 2 | 0.0 |
Haplotypes | 2 | 0.0 |
Models, Molecular | 5 | 0.0 |
*Polymorphism, Genetic | 10 | 0.0 |
Cohort Studies | 6 | 0.0 |
Cytochrome P-450 CYP1A2/metabolism | 2 | 2.0 |
Gene Expression Regulation, Enzymologic | 8 | 1.0 |
Polymerase Chain Reaction | 11 | 0.0 |
Polymorphism, Genetic/*genetics | 7 | 0.0 |
Polymorphism, Single-Stranded Conformational | 5 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
RNA, Messenger/genetics | 12 | 0.0 |
Transcription Factors/*genetics | 4 | 0.0 |
Enhancer Elements (Genetics) | 5 | 1.0 |
Gene Expression Regulation/drug effects | 10 | 1.0 |
Helix-Loop-Helix Motifs | 16 | 6.0 |
Precipitin Tests | 6 | 0.0 |
Receptors, Aryl Hydrocarbon/drug effects/genetics/*metabolism | 3 | 100.0 |
Teratogens/toxicity | 3 | 30.0 |
Tetrachlorodibenzodioxin/toxicity | 14 | 66.0 |
Trans-Activators/genetics/metabolism | 2 | 1.0 |
Breast Neoplasms/drug therapy | 2 | 6.0 |
Receptors, Aryl Hydrocarbon/*drug effects/physiology | 3 | 100.0 |
Tetrachlorodibenzodioxin/pharmacology | 52 | 62.0 |
Receptors, Aryl Hydrocarbon/*metabolism | 50 | 70.0 |
Saccharomyces cerevisiae | 3 | 1.0 |
Structure-Activity Relationship | 15 | 0.0 |
Cytochrome P-450 CYP1A1/*biosynthesis | 10 | 40.0 |
Cytochrome P-450 CYP1A2/biosynthesis | 3 | 25.0 |
DNA/drug effects/metabolism | 2 | 4.0 |
Enzyme Induction/drug effects | 17 | 4.0 |
Fatty Acids, Unsaturated/pharmacology | 2 | 3.0 |
COS Cells | 13 | 0.0 |
Cercopithecus aethiops | 3 | 0.0 |
DNA-Binding Proteins/metabolism | 14 | 0.0 |
Dioxins/metabolism | 6 | 85.0 |
Transcription Factors/metabolism | 18 | 1.0 |
Transcription, Genetic/*physiology | 2 | 1.0 |
*Aryl Hydrocarbon Hydroxylases | 15 | 1.0 |
Cell Division | 5 | 0.0 |
Drug Interactions | 8 | 0.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Receptors, Aryl Hydrocarbon/metabolism | 16 | 41.0 |
Tetrachlorodibenzodioxin/*toxicity | 17 | 35.0 |
Case-Control Studies | 7 | 0.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics | 3 | 21.0 |
Gene Expression Profiling | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 8 | 0.0 |
Lung Neoplasms/enzymology/*genetics | 4 | 11.0 |
Oxidation-Reduction | 5 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Predictive Value of Tests | 3 | 0.0 |
Age Factors | 8 | 0.0 |
Benzofurans/toxicity | 2 | 50.0 |
*Disease Models, Animal | 2 | 0.0 |
Immunohistochemistry | 11 | 0.0 |
Random Allocation | 3 | 0.0 |
Receptors, Aryl Hydrocarbon/*agonists | 2 | 66.0 |
Tetrachlorodibenzodioxin/*analogs & derivatives/*toxicity | 2 | 100.0 |
Child | 5 | 0.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Environmental Pollutants/*poisoning | 3 | 33.0 |
Japan | 2 | 0.0 |
Linkage Disequilibrium | 3 | 0.0 |
Tetrachlorodibenzodioxin/*poisoning | 2 | 66.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Disease Susceptibility | 3 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Chromosome Mapping | 7 | 0.0 |
Dioxins | 2 | 100.0 |
Disease Models, Animal | 4 | 0.0 |
Receptors, Aryl Hydrocarbon/*genetics/metabolism | 11 | 100.0 |
Alanine | 3 | 3.0 |
Proline | 2 | 3.0 |
Binding, Competitive | 17 | 0.0 |
Blotting, Western | 15 | 0.0 |
Cytochrome P-450 CYP1A1/genetics/*metabolism | 5 | 19.0 |
DNA/metabolism | 14 | 0.0 |
Enzyme Activation | 3 | 0.0 |
Promoter Regions (Genetics)/drug effects | 3 | 2.0 |
Protein Conformation | 3 | 0.0 |
Trans-Activation (Genetics)/*drug effects | 3 | 3.0 |
Cell Line | 41 | 0.0 |
Chromatin/metabolism | 2 | 0.0 |
Cytochrome P-450 CYP1A1/*metabolism | 7 | 21.0 |
Dimerization | 12 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Protein Binding | 34 | 0.0 |
*Transcription, Genetic | 9 | 0.0 |
Bronchial Hyperreactivity/immunology/*physiopathology | 2 | 50.0 |
Epithelial Cells/drug effects/metabolism | 3 | 3.0 |
Lymphocyte Activation | 2 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Signal Transduction/physiology | 5 | 0.0 |
Environmental Pollutants/*pharmacology | 4 | 57.0 |
Jurkat Cells | 2 | 0.0 |
Kinetics | 9 | 0.0 |
RNA, Messenger/biosynthesis | 10 | 0.0 |
Tetrachlorodibenzodioxin/*pharmacology | 22 | 34.0 |
*Trans-Activation (Genetics) | 8 | 1.0 |
Binding Sites | 24 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Receptors, Aryl Hydrocarbon/chemistry/*metabolism | 5 | 100.0 |
Blotting, Northern | 13 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 8 | 0.0 |
Immunoblotting | 7 | 0.0 |
Luciferases/metabolism | 3 | 0.0 |
Methylcholanthrene/pharmacology | 9 | 25.0 |
Monocytes/*metabolism | 2 | 0.0 |
Transcription, Genetic | 20 | 0.0 |
Cytochrome P-450 CYP1A1/drug effects/*metabolism | 2 | 66.0 |
Receptors, Aryl Hydrocarbon/drug effects | 2 | 66.0 |
Endometrium/metabolism | 2 | 3.0 |
Placenta/metabolism | 2 | 1.0 |
Pregnancy | 5 | 0.0 |
Tissue Distribution | 13 | 0.0 |
Transcription Factors/genetics/*metabolism | 10 | 1.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Biological Transport/drug effects | 2 | 0.0 |
Breast Neoplasms | 9 | 3.0 |
Cytochrome P-450 CYP1A1/biosynthesis/genetics | 7 | 43.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
Transcription, Genetic/drug effects | 10 | 1.0 |
Benzo(a)pyrene/pharmacology | 6 | 28.0 |
DNA, Complementary | 3 | 0.0 |
Gene Expression Regulation, Enzymologic/drug effects/*physiology | 2 | 7.0 |
Promoter Regions (Genetics) | 20 | 0.0 |
Proteins/*genetics | 3 | 0.0 |
Receptors, Aryl Hydrocarbon/metabolism/*physiology | 3 | 75.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Genome | 2 | 0.0 |
Phylogeny | 6 | 0.0 |
RNA/metabolism | 3 | 0.0 |
Trans-Activation (Genetics) | 8 | 0.0 |
*Enhancer Elements (Genetics) | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
Electrophoresis | 2 | 0.0 |
Exons | 5 | 0.0 |
France | 2 | 0.0 |
Genetic Predisposition to Disease | 5 | 0.0 |
Sequence Analysis, DNA | 9 | 0.0 |
Continental Population Groups/genetics | 2 | 2.0 |
Cytochrome P-450 CYP1A1/*genetics | 7 | 3.0 |
DNA/genetics/metabolism | 2 | 0.0 |
DNA Mutational Analysis | 5 | 0.0 |
Electrophoretic Mobility Shift Assay | 5 | 1.0 |
Enzyme Induction/genetics | 3 | 18.0 |
Mutation/genetics | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
RNA, Messenger/genetics/metabolism | 13 | 0.0 |
Receptors, Aryl Hydrocarbon/*genetics/*metabolism | 6 | 100.0 |
Dioxins/*poisoning | 2 | 66.0 |
*Environmental Exposure | 3 | 4.0 |
Neoplasms/*chemically induced | 2 | 8.0 |
Receptors, Aryl Hydrocarbon/drug effects/physiology | 4 | 100.0 |
Risk Assessment | 5 | 0.0 |
United States | 2 | 0.0 |
*Cloning, Molecular | 2 | 0.0 |
Genes, Reporter | 20 | 1.0 |
Radioligand Assay | 4 | 0.0 |
Receptors, Aryl Hydrocarbon/chemistry/*genetics/*metabolism | 2 | 100.0 |
Sequence Alignment | 11 | 0.0 |
Tetrachlorodibenzodioxin/*metabolism | 3 | 42.0 |
Cell Cycle/drug effects | 3 | 0.0 |
Dioxins/*pharmacology | 4 | 28.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 4 | 0.0 |
Gene Silencing/*drug effects | 2 | 40.0 |
Stilbenes/*pharmacology | 4 | 7.0 |
DNA Primers/genetics | 6 | 0.0 |
Gene Expression | 13 | 0.0 |
Phosphoproteins/*genetics | 2 | 0.0 |
Recombinant Proteins/genetics/metabolism | 8 | 1.0 |
Sequence Deletion | 9 | 0.0 |
Transcription Factors/genetics/metabolism | 7 | 1.0 |
beta-Naphthoflavone/pharmacology | 2 | 6.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Models, Animal | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*biosynthesis | 3 | 18.0 |
Cytochrome P-450 CYP1A2/*biosynthesis | 3 | 27.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Receptors, Aryl Hydrocarbon/*drug effects/*physiology | 2 | 100.0 |
Genes, Reporter/genetics | 3 | 1.0 |
Polymorphism, Genetic | 5 | 0.0 |
Nuclear Proteins/metabolism | 10 | 1.0 |
Transcription, Genetic/*drug effects | 5 | 1.0 |
Gestational Age | 4 | 0.0 |
Carcinoma, Hepatocellular | 6 | 1.0 |
Liver Neoplasms | 3 | 1.0 |
Polychlorinated Biphenyls/*pharmacology | 2 | 14.0 |
Rats, Wistar | 3 | 0.0 |
Lung/*enzymology | 3 | 4.0 |
Mutation | 8 | 0.0 |
Aged, 80 and over | 9 | 0.0 |
Glutathione Transferase/*genetics/metabolism | 2 | 2.0 |
Receptors, Aryl Hydrocarbon/*genetics/physiology | 2 | 100.0 |
Smoking/*adverse effects | 3 | 1.0 |
Guinea Pigs | 7 | 0.0 |
Carcinogens/pharmacology | 3 | 3.0 |
Hamsters | 5 | 0.0 |
Oxidative Stress | 2 | 0.0 |
Receptors, Aryl Hydrocarbon/antagonists & inhibitors/*metabolism | 3 | 100.0 |
Receptors, Aryl Hydrocarbon/*physiology | 11 | 61.0 |
Models, Biological | 8 | 0.0 |
Regulatory Sequences, Nucleic Acid | 9 | 1.0 |
Chickens | 2 | 0.0 |
Dioxins/*toxicity | 4 | 40.0 |
*Evolution, Molecular | 2 | 0.0 |
Rabbits | 6 | 0.0 |
Cytochrome P-450 CYP1A1/biosynthesis/metabolism | 3 | 60.0 |
Apoptosis | 2 | 0.0 |
Gene Expression/drug effects | 9 | 1.0 |
In Vitro | 8 | 0.0 |
Receptors, Aryl Hydrocarbon/deficiency/genetics/*metabolism | 2 | 66.0 |
Response Elements | 3 | 1.0 |
Signal Transduction/drug effects | 5 | 0.0 |
Breast Neoplasms/*pathology | 3 | 1.0 |
Receptors, Aryl Hydrocarbon/*antagonists & inhibitors | 3 | 75.0 |
Receptors, Estrogen/metabolism | 4 | 1.0 |
Tumor Cells, Cultured/drug effects | 3 | 0.0 |
Uterus/drug effects | 2 | 20.0 |
Saccharomyces cerevisiae/genetics | 3 | 0.0 |
Signal Transduction | 13 | 0.0 |
5' Untranslated Regions/genetics | 3 | 2.0 |
*Chromosome Mapping | 2 | 0.0 |
Consensus Sequence | 6 | 0.0 |
Genomic Library | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
*Promoter Regions (Genetics) | 8 | 0.0 |
Repressor Proteins/*genetics | 4 | 1.0 |
Restriction Mapping | 3 | 0.0 |
Bronchial Provocation Tests/methods | 2 | 40.0 |
Bronchoconstrictor Agents/*diagnostic use | 2 | 100.0 |
Methacholine Chloride/*diagnostic use | 2 | 100.0 |
Regression Analysis | 3 | 0.0 |
Breast Neoplasms/*genetics/pathology | 2 | 0.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Gene Frequency | 7 | 0.0 |
Isoenzymes/genetics | 2 | 0.0 |
RNA, Neoplasm/genetics/metabolism | 3 | 2.0 |
Receptors, Aryl Hydrocarbon/genetics | 6 | 66.0 |
Introns | 2 | 0.0 |
Transcription Factors/genetics | 3 | 0.0 |
Androgen Antagonists/*pharmacology | 3 | 14.0 |
Genes, Reporter/drug effects | 2 | 20.0 |
*Receptors, Aryl Hydrocarbon | 4 | 14.0 |
Tetrachlorodibenzodioxin/metabolism/pharmacology | 5 | 83.0 |
Trans-Activation (Genetics)/drug effects | 10 | 4.0 |
Biotransformation | 3 | 0.0 |
Carcinogens/pharmacokinetics | 2 | 13.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics/metabolism | 2 | 13.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Liver/drug effects/enzymology | 2 | 3.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 2 | 1.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
Cattle | 5 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics | 3 | 1.0 |
Colonic Neoplasms/metabolism | 2 | 3.0 |
Cytochrome P-450 CYP1A1/biosynthesis/*genetics | 2 | 25.0 |
Liver Neoplasms/*metabolism | 2 | 2.0 |
Estrogen Receptor alpha | 11 | 4.0 |
Catalysis | 2 | 0.0 |
Bronchial Hyperreactivity/*physiopathology | 2 | 28.0 |
*Bronchial Provocation Tests | 2 | 18.0 |
*Alternative Splicing | 2 | 0.0 |
Oxygen/*metabolism | 2 | 1.0 |
Prognosis | 2 | 0.0 |
Cloning, Molecular | 15 | 0.0 |
Phenotype | 5 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis | 5 | 5.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Liver/cytology/*drug effects/metabolism | 2 | 12.0 |
Liver Neoplasms/*metabolism/pathology | 2 | 2.0 |
Organ Size/drug effects | 2 | 2.0 |
Receptors, Aryl Hydrocarbon/*biosynthesis/genetics | 3 | 100.0 |
Statistics | 2 | 0.0 |
Transcription Factors/*biosynthesis/genetics | 2 | 2.0 |
Binding Sites/genetics | 4 | 0.0 |
Down-Regulation/drug effects | 3 | 1.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
Protein-Serine-Threonine Kinases/*metabolism | 2 | 0.0 |
*Repressor Proteins | 2 | 0.0 |
Down-Regulation | 8 | 0.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
G1 Phase/drug effects | 2 | 1.0 |
Phosphorylation/drug effects | 2 | 0.0 |
Cell Survival/drug effects | 3 | 0.0 |
Cytochrome P-450 CYP1A1/*drug effects/metabolism | 2 | 50.0 |
Cytochrome P-450 Enzyme System/metabolism | 4 | 1.0 |
Teratogens/*toxicity | 4 | 22.0 |
Biological Assay | 2 | 0.0 |
Luciferases/genetics | 2 | 0.0 |
Asthma/*physiopathology | 2 | 7.0 |
*Alleles | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide/*pharmacology | 3 | 60.0 |
Benzo(a)pyrene/*pharmacology | 4 | 40.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 4 | 1.0 |
Tumor Cells, Cultured/drug effects/metabolism | 3 | 1.0 |
Cytochrome P-450 CYP1A1/*biosynthesis/genetics | 6 | 24.0 |
DNA, Complementary/genetics | 7 | 0.0 |
Estradiol/metabolism/pharmacology | 4 | 30.0 |
Gene Expression Regulation, Neoplastic/drug effects | 2 | 0.0 |
Indoles/pharmacology | 2 | 0.0 |
Receptors, Aryl Hydrocarbon/*agonists/genetics/metabolism | 2 | 100.0 |
Phosphorylation | 6 | 0.0 |
Receptors, Aryl Hydrocarbon/*chemistry | 4 | 100.0 |
Neoplasms/metabolism | 2 | 2.0 |
Two-Hybrid System Techniques | 3 | 0.0 |
Breast Neoplasms/pathology | 3 | 2.0 |
Cathepsin D/*genetics | 2 | 12.0 |
Estradiol/*pharmacology | 2 | 0.0 |
Cell Nucleus/drug effects/metabolism | 2 | 3.0 |
Drug Synergism | 2 | 0.0 |
Gene Expression Regulation, Enzymologic/drug effects | 4 | 2.0 |
Liver/metabolism | 7 | 0.0 |
Carcinogenicity Tests | 2 | 2.0 |
Cytochrome P-450 CYP1A1/metabolism | 9 | 13.0 |
Drug Administration Schedule | 2 | 0.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 6 | 0.0 |
Receptors, Aryl Hydrocarbon/genetics/metabolism/*physiology | 3 | 100.0 |
9,10-Dimethyl-1,2-benzanthracene | 2 | 13.0 |
Estradiol/*analogs & derivatives/pharmacology | 2 | 4.0 |
Estrogen Antagonists/pharmacology | 5 | 5.0 |
DNA/*metabolism | 6 | 1.0 |
Heat-Shock Proteins 90/metabolism | 3 | 10.0 |
Receptors, Aryl Hydrocarbon/chemistry/genetics/*metabolism | 4 | 100.0 |
Signal Transduction/*physiology | 3 | 0.0 |
Gene Expression/*drug effects | 6 | 2.0 |
*Gene Expression Regulation, Developmental | 3 | 0.0 |
In Situ Hybridization | 8 | 0.0 |
RNA, Messenger/biosynthesis/drug effects | 2 | 3.0 |
Teratogens/pharmacology | 4 | 40.0 |
Environmental Pollutants/toxicity | 5 | 45.0 |
Receptors, Aryl Hydrocarbon/physiology | 2 | 22.0 |
Luminescent Proteins/genetics/metabolism | 2 | 1.0 |
Cell Division/drug effects | 11 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
Enzyme Inhibitors/*pharmacology | 6 | 0.0 |
Receptors, Aryl Hydrocarbon/*antagonists & inhibitors/physiology | 2 | 100.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
Environmental Pollutants/pharmacology | 8 | 66.0 |
Estradiol/pharmacology | 7 | 2.0 |
Proteasome Endopeptidase Complex | 3 | 0.0 |
Receptor Cross-Talk/drug effects | 2 | 50.0 |
Receptors, Aryl Hydrocarbon/agonists/*metabolism | 6 | 100.0 |
Diet | 2 | 0.0 |
Flavonoids/*pharmacology | 6 | 7.0 |
Body Burden | 3 | 16.0 |
*Imidazolidines | 2 | 10.0 |
Mesocricetus | 2 | 1.0 |
Cytochrome P-450 CYP1A1/*genetics/*metabolism | 2 | 66.0 |
Lymphocytes/enzymology | 3 | 3.0 |
Antibiotics, Antineoplastic/pharmacology | 2 | 2.0 |
Cell Nucleus/*metabolism | 4 | 0.0 |
Recombinant Fusion Proteins/metabolism | 4 | 0.0 |
*Gene Expression | 2 | 0.0 |
Carcinogens/*toxicity | 3 | 2.0 |
Liver/*drug effects/enzymology | 3 | 6.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Imidazoles/*pharmacology | 2 | 2.0 |
Benzo(a)pyrene/toxicity | 3 | 18.0 |
Biological Transport | 3 | 0.0 |
Quinones/*toxicity | 2 | 40.0 |
Gene Expression Regulation/*drug effects/physiology | 2 | 11.0 |
Cell Cycle | 3 | 0.0 |
*Cell Cycle Proteins | 2 | 0.0 |
Repressor Proteins/metabolism | 2 | 1.0 |
Retinoblastoma Protein/*metabolism | 3 | 1.0 |
Transcription Factors/*metabolism | 10 | 0.0 |
Caco-2 Cells | 2 | 0.0 |
Receptors, Estrogen/genetics/*metabolism | 3 | 8.0 |
Polychlorinated Biphenyls/pharmacology | 4 | 50.0 |
Xenobiotics | 3 | 42.0 |
Heat-Shock Proteins 90/*metabolism | 2 | 8.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Peptide Hydrolases/metabolism | 2 | 1.0 |
Antibody Specificity | 2 | 0.0 |
Receptor Cross-Talk | 3 | 7.0 |
Polycyclic Hydrocarbons, Aromatic/toxicity | 2 | 33.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Cytochrome P-450 CYP1A1/genetics/metabolism | 7 | 23.0 |
*Signal Transduction | 5 | 0.0 |
DNA-Binding Proteins/*metabolism | 8 | 0.0 |
Nuclear Proteins/*metabolism | 5 | 0.0 |
Centrifugation, Density Gradient | 2 | 0.0 |
Cytosol/metabolism | 10 | 1.0 |
Dogs | 2 | 0.0 |
Liver/*metabolism | 3 | 0.0 |
Receptors, Estrogen/*metabolism | 5 | 2.0 |
Subcellular Fractions | 2 | 1.0 |
Carcinogens/*pharmacology | 3 | 4.0 |
*Down-Regulation | 3 | 0.0 |
Up-Regulation | 5 | 0.0 |
Apoptosis/drug effects | 3 | 0.0 |
Aryl Hydrocarbon Hydroxylases/genetics | 2 | 8.0 |
Cell Line, Tumor | 18 | 0.0 |
Cell Nucleus/metabolism | 12 | 0.0 |
Protein Transport/drug effects | 2 | 3.0 |
Response Elements/genetics | 9 | 5.0 |
Anticarcinogenic Agents/*pharmacology | 4 | 4.0 |
Neoplasms/*genetics | 2 | 0.0 |
DNA Footprinting | 2 | 0.0 |
DNA Methylation | 2 | 0.0 |
Ultraviolet Rays | 2 | 0.0 |
Hela Cells | 10 | 0.0 |
Receptors, Aryl Hydrocarbon/genetics/metabolism | 3 | 50.0 |
Signal Transduction/*drug effects | 3 | 0.0 |
Exons/genetics | 2 | 0.0 |
Protein Processing, Post-Translational/drug effects | 2 | 1.0 |
Retinoblastoma Protein/metabolism | 2 | 0.0 |
Breast Neoplasms/metabolism | 3 | 2.0 |
Enzyme Inhibitors/metabolism | 2 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
Breast Neoplasms/*enzymology/pathology | 2 | 6.0 |
Dimethyl Sulfoxide/pharmacology | 2 | 2.0 |
Prostate-Specific Antigen/genetics/metabolism | 2 | 50.0 |
Organ Culture Techniques | 2 | 0.0 |
Estrogen Antagonists/*pharmacology | 4 | 5.0 |
Receptors, Aryl Hydrocarbon/*agonists/physiology | 2 | 100.0 |
Carcinoma, Hepatocellular/metabolism | 2 | 2.0 |
Liver Neoplasms, Experimental/metabolism | 2 | 10.0 |
Luciferases/biosynthesis/genetics | 3 | 5.0 |
Methoxsalen/pharmacology | 2 | 25.0 |
Tetrachlorodibenzodioxin/metabolism | 6 | 54.0 |
RNA, Small Interfering/genetics | 2 | 1.0 |
Receptors, Aryl Hydrocarbon/antagonists & inhibitors/genetics/*metabolism | 2 | 100.0 |
Dioxins/pharmacology | 6 | 66.0 |
Liver Neoplasms/metabolism/pathology | 2 | 12.0 |
Vehicle Emissions/*toxicity | 2 | 25.0 |
Carrier Proteins/genetics/*metabolism | 2 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
*Proteins | 3 | 0.0 |
Double-Blind Method | 2 | 0.0 |
Gene Expression Regulation, Developmental/drug effects | 2 | 7.0 |
Benz(a)Anthracenes/pharmacology | 3 | 60.0 |
Logistic Models | 2 | 0.0 |
Methylcholanthrene/*pharmacology | 2 | 25.0 |
Receptors, Aryl Hydrocarbon/genetics/*physiology | 3 | 60.0 |
Environment | 2 | 2.0 |
Prostatic Neoplasms/*metabolism | 2 | 1.0 |
Receptors, Aryl Hydrocarbon/*metabolism/physiology | 2 | 100.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*metabolism | 3 | 0.0 |
Stromal Cells/drug effects/metabolism | 2 | 11.0 |
Oligonucleotide Probes | 2 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Pharmaceutical Preparations/metabolism | 2 | 6.0 |
Tetrachlorodibenzodioxin/analogs & derivatives/pharmacology | 2 | 100.0 |
Tetrachlorodibenzodioxin/*metabolism/pharmacology | 4 | 100.0 |
*Risk Assessment | 3 | 16.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
DNA Adducts/metabolism | 2 | 5.0 |
Enhancer Elements (Genetics)/genetics | 2 | 2.0 |
Plasmids/genetics | 2 | 0.0 |
Transcription Factors/chemistry/*metabolism | 2 | 1.0 |
Reactive Oxygen Species/metabolism | 4 | 1.0 |
beta-Galactosidase/genetics | 2 | 1.0 |
English Abstract | 2 | 0.0 |
Signal Transduction/drug effects/*physiology | 2 | 0.0 |
Azo Compounds/pharmacology | 2 | 33.0 |
Cytochrome P-450 CYP1A1/*biosynthesis/metabolism | 2 | 33.0 |
Transcription Factors/biosynthesis | 2 | 2.0 |
Conserved Sequence | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Receptors, Aryl Hydrocarbon/agonists | 2 | 50.0 |
Cell Compartmentation | 3 | 0.0 |
*Transcription Factors | 5 | 0.0 |
Luciferases/biosynthesis | 4 | 4.0 |
Receptors, Aryl Hydrocarbon/*biosynthesis | 6 | 100.0 |
Transforming Growth Factor beta/*pharmacology | 2 | 0.0 |
Antioxidants/pharmacology | 2 | 1.0 |
Indoles/*pharmacology | 2 | 2.0 |
Saccharomyces cerevisiae/genetics/*metabolism | 2 | 5.0 |
*Transcription, Genetic/drug effects | 2 | 1.0 |
Cytochrome P-450 CYP1A1/*genetics/metabolism | 3 | 13.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Quinones/pharmacology | 2 | 1.0 |
Cytochrome P-450 CYP1A1/*biosynthesis/*genetics | 2 | 66.0 |
Liver/*enzymology | 2 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Forecasting | 3 | 0.0 |
Prevalence | 2 | 0.0 |
Polycyclic Hydrocarbons, Aromatic/*pharmacology | 2 | 33.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
*Helix-Loop-Helix Motifs | 3 | 3.0 |
Macromolecular Substances | 8 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 2 | 1.0 |
Cycloheximide/pharmacology | 3 | 0.0 |
*Chromosomes, Human, Pair 7 | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/biosynthesis | 4 | 36.0 |
Breast Neoplasms/metabolism/pathology | 3 | 7.0 |
Receptors, Aryl Hydrocarbon/chemistry/*genetics | 2 | 66.0 |
Cell Line, Tumor/drug effects | 2 | 8.0 |
Indoles/chemistry/metabolism/*pharmacology | 2 | 66.0 |
Liver Neoplasms, Experimental/pathology | 2 | 28.0 |
Carcinogens/toxicity | 3 | 5.0 |
Retinoid X Receptors | 2 | 0.0 |
Transcription Factors/physiology | 3 | 1.0 |
Tretinoin/*pharmacology | 2 | 0.0 |
Animals, Newborn | 2 | 0.0 |
DNA Probes | 3 | 0.0 |
Cell Cycle/physiology | 2 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Syndrome | 2 | 0.0 |
MAP Kinase Signaling System/drug effects | 2 | 2.0 |
Mitogen-Activated Protein Kinases/*antagonists & inhibitors/metabolism | 3 | 21.0 |
DNA/chemistry | 2 | 0.0 |
Transcription Factors/*chemistry | 3 | 6.0 |
Protein Biosynthesis | 3 | 0.0 |
Lung Neoplasms/pathology | 2 | 3.0 |
*Flavanones | 2 | 8.0 |
Oligodeoxyribonucleotides/chemistry | 3 | 1.0 |
DNA, Complementary/*genetics | 2 | 0.0 |
DNA, Complementary/isolation & purification | 2 | 1.0 |
Plasmids | 2 | 0.0 |
Embryo/*metabolism | 2 | 3.0 |
Embryonic and Fetal Development/*genetics/*physiology | 2 | 100.0 |
Xenobiotics/pharmacology | 3 | 13.0 |
Luciferases/genetics/metabolism | 2 | 0.0 |
Receptors, Aryl Hydrocarbon/*agonists/*metabolism | 2 | 100.0 |
Benz(a)Anthracenes/toxicity | 2 | 33.0 |
Affinity Labels | 5 | 9.0 |
Iodine Radioisotopes | 2 | 0.0 |
Spodoptera | 2 | 0.0 |
Cell Count | 2 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Protein Transport | 2 | 0.0 |
Transcription Factors | 2 | 2.0 |
p38 Mitogen-Activated Protein Kinases | 2 | 0.0 |
Temperature | 2 | 0.0 |
Culture Techniques | 2 | 0.0 |
Transcription, Genetic/physiology | 2 | 1.0 |
Proteins/*chemistry | 2 | 2.0 |
Receptors, Aryl Hydrocarbon | 7 | 43.0 |
*Genes, Reporter | 2 | 4.0 |
Receptors, Drug/*metabolism | 3 | 12.0 |
Cytosol/drug effects/metabolism | 2 | 9.0 |
Protein Binding/physiology | 2 | 0.0 |
beta-Naphthoflavone/metabolism | 2 | 100.0 |
Gene Deletion | 2 | 0.0 |
Estrogens/metabolism | 2 | 2.0 |
JNK Mitogen-Activated Protein Kinases | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
Polybrominated Biphenyls/*toxicity | 2 | 66.0 |
*Ligands | 2 | 8.0 |
*Monosaccharide Transport Proteins | 2 | 5.0 |
Receptors, Estrogen/*genetics | 2 | 2.0 |
Methylcholanthrene/toxicity | 2 | 40.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Gene Expression Regulation, Enzymologic/drug effects/physiology | 2 | 6.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*metabolism | 2 | 4.0 |
Polycyclic Hydrocarbons, Aromatic/*metabolism | 2 | 11.0 |
